Clinical Trial Update: A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

View source ↗

Summary

A clinical trial update describes long-term safety outcomes in patients previously treated with RP1, RP2, or RP3 and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Melanoma

Drugs mentioned

• RP1
• RP2
• RP3

Snippet

Sponsor: Replimune, Inc. | Conditions: Melanoma, Metastatic Melanoma | Status: RECRUITING